Trial Profile

Cynergy - The CYPHER-NEVO Registry. An Observational Registry, to Evaluate the Safety and Performance of the NEVO Sirolimus-eluting Coronary Stent in Routine Clinical Practice, and to Compare Its Safety and Performance With the CYPHER Select Plus Sirolimus-eluting Coronary Stent (SES).

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 15 Jul 2011

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sirolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis; Myocardial infarction
Focus Therapeutic Use
Acronyms CYNERGY
Sponsors Cordis Corporation

11 Jul 2011 Planned End Date changed from 1 Apr 2015 to 1 Dec 2011 as reported by ClinicalTrials.gov.
11 Jul 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
09 Sep 2010 Planned end date changed from 1 Apr 2014 to 1 Apr 2015 as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com